Gilead Sciences (GILD) 117.66 $GILD
Bristol-Myers Squibb Gets a Mixed Message From Investors
Brian Orelli, The Motley Fool - Motley Fool - 1 hr 18 mins ago
Source: Bristol-Myers Squibb When a company beats revenue expectations by a wide margin, $4.2 billion actual versus a $3.7 billion consensus, as Bristol-Myers Squibb did, you'd expect shares to skyrocket. Instead the pharma is sitting down 1%...
GILD: 117.66 (+0.22), BMY: 68.24 (-1.13)
Gilead Sciences Leads 3 Top-Rated Big Cap Stocks
at Investor's Business Daily - Wed Jul 22, 9:12PM CDT
Combining superior fundamentals with strong chart action can pinpoint top stock watch candidates such as Gilead Sciences. Today's Screen Of The Day, Top Fundamentals, features highly rated firms with three-year sales and earnings growth rates of at...
NFLX: 110.10 (-1.40), AMZN: 482.18 (-6.09), LEN: 52.46 (-0.73), GILD: 117.66 (+0.22), GOOGL: 674.73 (-20.37), MSFT: 46.11 (+0.57), BABA: 83.88 (-0.27)
Gilead (GILD) Presents Encouraging Data on HIV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 22, 1:55PM CDT
Gilead Sciences, Inc. (GILD) presented encouraging detailed 48-week data from the phase III study on tenofovir alafenamide-based regimen for the treatment of HIV.
JNJ: 100.20 (+0.02), GILD: 117.66 (+0.22), SNSS: 3.47 (-0.05), AMAG: 71.31 (-1.23)
US Blood Cancer Drug Market & Pipeline Analysis 2015
M2 - Wed Jul 22, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hp4cd3/us_blood_cancer) has announced the addition of the "US Blood Cancer Drug Market & Pipeline Analysis 2015" report to their offering. Chemotherapeutic drugs are widely used therapeutics for the treatment of blood cancer in US. The future would witness a novel chemotherapeutics which are currently under various stages of research and development. Liposomal, pegylated and other improved versions are being made to offer higher therapeutic benefit along with minimized side effects. This will also help in increasing the number of indications and market volume by introduction of new chemotherapeutic products. They would have higher safety and efficacy levels as compared to their traditional counterparts. It will help in occupying large market shares and compete effectively with presently available drugs. Monoclonal antibodies are known for their superior pharmacological profiles and fewer side effects due to which they are widely accepted. Few monoclonal antibodies have been already introduced in US market. They have been able to generate significant revenues which are encouraging pharmaceutical companies to venture in this segment. Tyrosine kinase inhibitors are another major component of this market which has received lots of commercial success owing to their superior pharmacological efficacy. Both of them are far superior then chemotherapeutics and it is expected that blood cancer drugs belonging to different drug categories would be introduced in US market. Innovative blood cancer therapeutics is likely to generate huge revenues for the pharmaceutical companies in the next few years. However, few hurdles have to be passed like heterogeneous nature of blood cancer; it consists of different cells with different functions and it becomes difficult to eliminate them with single type of therapeutic. In this regard, only single therapeutic for different blood cancers have been introduced in US market till date. This strategy is likely to be followed by other pharmaceutical companies due to which competition in multiple blood cancer segments will increase. Market introduction of such therapeutics is likely to be widely accepted leading to generation of significant revenues. More blood cancer therapeutics is likely to enter in US market due to which its size will increase. "US Blood Cancer Drug Market & Pipeline Analysis 2015" Report Highlights: - Blood Cancer Incidence & Prevalence - Blood Cancer Drug Market Overview - Blood Cancer Drug Market Dynamics - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline Insight - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline: 435 Drugs - Majority Drugs in Phase-I Clinical Trials: 128 Drugs - Marketed Leukemia, Lymphoma & Myeloma Drug Clinical & Patent Analysis - Marketed Leukemia, Lymphoma & Myeloma Drug: 48 Drugs Key Topics Covered: 1. US Blood Cancer Incidence & Prevalence 2. US Blood Cancer Drug Market Overview 3. US Blood Cancer Drug Market Dynamics 4. US Blood Cancer Drug Market Future Prospects 5. Mechanism of Blood Cancer Therapeutics 6. Leukemia Drug Clinical Pipeline by Company & Phase 7. Marketed Leukemia Drug Clinical Insight 8. Lymphoma Drug Clinical Pipeline by Company & Phase 9. Marketed Lymphoma Drug Clinical Insight 10. Multiple Myeloma Drug Clinical Pipeline by Company & Phase 11. Marketed Multiple Myeloma Drug Clinical Insight 12. Multiple Blood Cancer Drug Clinical Pipeline by Company & Phase 13. Marketed Multiple Blood Cancer Drug Clinical Insight 14. Competitive Landscape - ARIAD Pharmaceuticals - Actelion Pharmaceuticals - Amgen - Astellas Pharma - Baxter BioScience - Bayer HealthCare Pharmaceuticals Inc. - Biogen Idec - Bristol-Myers Squibb - CASI Pharmaceuticals - Celera Genomics Group - Celgene Corporation - Eisai Co Ltd - Genmab - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Millennium Pharmaceuticals - Nova Laboratories - Novartis - Onxeo SA - Onyx Pharmaceuticals - Otsuka Pharmaceutical - Pfizer - Roche - SRI International - Scripps Clinic - Seattle Genetics - Southern Research Institute - Tekmira Pharmaceuticals Corporation - Teva Pharmaceutical Industries - Yakult Honsha For more information visit http://www.researchandmarkets.com/research/hp...ood_cancer
BIIB: 385.05 (-6.69), TKMR: 10.73 (+0.39), AMGN: 164.10 (-0.15), GSK: 42.00 (-0.30), BMY: 68.24 (-1.13), CASI: 1.64 (-0.07), JNJ: 100.20 (+0.02), GILD: 117.66 (+0.22), TEVA: 62.51 (unch), ARIA: 8.05 (-0.18), NVS: 103.05 (+1.75), CELGZ: 2.20 (-0.09)
Gilead Sciences' Next Big Move May Not Be What You're Thinking
George Budwell, The Motley Fool - Motley Fool - Wed Jul 22, 9:31AM CDT
Gilead Sciences ' rocket-like growth rate is starting to slow due to pushback from payers over the price of its flagship hepatitis C drugs Harvoni and Sovaldi, along with AbbVie 's competing combo drug, Viekira Pak, beginning to capture a somewhat...
GILD: 117.66 (+0.22)
Hedge Funds Love These 5 Big Stocks -- Should You?
at The Street - Wed Jul 22, 8:23AM CDT
Hedge funds have been piling into these stocks in the last few months. Should you be buying them too?
V: 71.75 (-0.22), LBTYA: 52.08 (-0.46), GILD: 117.66 (+0.22), BABA: 83.88 (-0.27)
Gilead Sciences to Release Second Quarter 2015 Financial Results on Tuesday, July 28, 2015
Business Wire - Tue Jul 21, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2015 financial results will be released on Tuesday, July 28, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead's management will host a conference call to discuss the company's financial results for the second quarter 2015 and provide a general business update.
GILD: 117.66 (+0.22)
Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF)
Business Wire - Tue Jul 21, 1:06PM CDT
Gilead Sciences, Inc. (NASDAQ:GILD) today announced detailed 48-week data from an open-label Phase 3 study (Study 109) evaluating its investigational once-daily single tablet regimen (STR) of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg (E/C/F/TAF) among 1,436 virologically suppressed adult patients switching from tenofovir disoproxil fumarate (TDF)-containing regimens. The study met its primary endpoint by demonstrating non-inferiority of E/C/F/TAF to the TDF-based regimens at Week 48. The study also demonstrated statistical superiority among patients with HIV-1 RNA levels less than 50 copies/mL at Week 48 and statistically significant improvements in bone and renal laboratory parameters. These data were presented in an oral session (session TUAB0102) at the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention (IAS) in Vancouver, Canada.
GILD: 117.66 (+0.22)
Why This Analyst Expects New Alzhemier’s Trials Could Produce the Most Important Drugs in History
ESTMZ - Tue Jul 21, 11:24AM CDT
Welcome to the July 21st edition of This Week on Estimize. We are pleased to be joined by Joe McCann, former biotech analyst and founder of Slingshot Insights, a company that works to provide professional caliber investment tools to sophisticated...
BIIB: 385.05 (-6.69), SPY: 210.18 (-1.19), GILD: 117.66 (+0.22), ZGNX: 20.27 (-0.71), UTHR: 175.10 (+0.50), RTRX: 34.18 (-0.75), LLY: 86.76 (+0.38), CELG: 139.01 (+0.75), XOMA: 1.04 (+0.04)
Gilead Sciences (GILD) Approaches New Downside Target of $117.22
Comtex SmarTrend(R) - Tue Jul 21, 11:06AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $118.33 today and has reached the first level of support at $117.71. Should the shares continue to fall, the support pivots of $117.22 and $116.11 will be of interest.
GILD: 117.66 (+0.22)
Sickle Cell Disease Pipeline Review, H1 2015 - 27 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rrc4sf/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Erytech Pharma SA - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sangamo BioSciences, Inc. - Sanofi - SynZyme Technologies, LLC For more information visit http://www.researchandmarkets.com/research/rr...ickle_cell
JNJ: 100.20 (+0.02), ISIS: 55.08 (-0.30), GILD: 117.66 (+0.22), PFE: 34.78 (-0.10), SGMO: 8.83 (-0.77), BMY: 68.24 (-1.13), NVS: 103.05 (+1.75), XLRN: 31.50 (-0.68)
The Best Deals in Value Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 21, 8:04AM CDT
Source: Federal Reserve Bank of New York via Facebook Investors may have suffered through the worst case of stock market "indigestion" in multiple generations between 2007 and 2009, but the subsequent bull market has produced some of the most...
F: 14.61 (+0.19), IBM: 161.73 (+1.38), GILD: 117.66 (+0.22), BAC: 18.18 (-0.27), AAPL: 125.16 (-0.06)
Nonalcoholic steatohepatitis (NASH) - 2015 Pipeline Analysis
M2 - Tue Jul 21, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kf56cl/nonalcoholic) has announced the addition of the "Nonalcoholic steatohepatitis (NASH) - Pipeline Analysis" report to their offering. This report gives comprehensive insight on the various drugs being developed for the treatment of NASH. The report covers all the drugs being developed in various phases (Discovery, Preclinical & Clinical development). The pipeline focuses on novel medicines covering small molecules, monoclonal antibodies, Recombinant proteins and RNA-based therapeutics, but excludes Off-label, symptom relief drugs, generic combinations. The report also covers hot targets in research for NASH treatments and disease progression biomarkers. This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Nonalcoholic steatohepatitis (NASH) Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future NASH treatment space. NASH is associated with fatty liver, hepatic inflammation, hepatocyte injury and fibrogenesis and may worsen into fibrosis or cirrhosis, liver failure and rarely into liver cancer. Currently, there are no approved drugs for NASH by U.S. Food and Drug Administration (FDA) and there a high unmet clinical need. NASH, if untreated can progress to liver-destroying cirrhosis and potentially cancer. Majority of the NASH pipeline drugs are from specialised small to mid pharmaceutical & biotech companies. As some of the candidates are nearing key R&D milestones, there is a huge competition among large pharmaceutical and biotech companies to acquire these assets. Gilead's acquisition of Phenex FXR program & Boehringer's acquisition of NASH clinical asset from Pharmaxis supports this trend. Diagnosis of NASH still requires histological confirmation and there is a great demand for specific non-invasive diagnosis for distinguishing NASH from other liver diseases. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH. There is a tremendous opportunity for upcoming therapies specific to NASH such as MAbs, RNA-based therapies & Recombinant proteins. These modalities may provide Anti-fibrosis, Anti-inflammatory and metabolic benefits. Key Topics Covered: 1. Report Description 2. Introduction 3. Hot Targets, Mechanisms & Therapies 4. Market Data 5. Pipeline Analysis 6. Small Molecules 7. Large Molecule 8. RNA-based Therapy 9. Recombinant Proteins 10. Antibodies 11. Large Molecules (Unspecified) 12. Other Molecules 13. NASH Drug Analysis based on Mechanisms 14. Major Players - Boehringer Ingelheim - Cerenis Therapeutics - Connexios Life Sciences - Genfit - Gilead Sciences - Intercept - Islet Sciences - Nimbus Therapeutics - Verva Pharmaceuticals - Viking Therapeutics For more information visit http://www.researchandmarkets.com/research/kf...nalcoholic
GILD: 117.66 (+0.22), VKTX: 6.02 (-0.44)
Are Any New FANGs Baring Their Teeth?
at The Street - Mon Jul 20, 10:27AM CDT
The fearsome foursome have been reborn.
AGN: 314.95 (-0.40), AMBA: 122.99 (+0.49), NFLX: 110.10 (-1.40), BIIB: 385.05 (-6.69), GPRO: 63.95 (+2.27), AMZN: 482.18 (-6.09), VRX: 253.84 (+14.92), GILD: 117.66 (+0.22), FB: 95.44 (-1.60), GOOGL: 674.73 (-20.37), REGN: 556.61 (+0.08), CELG: 139.01 (+0.75), MS: 39.94 (-0.60)
Critical Alerts For Linn Energy, Gilead Sciences, BP, Alcoa and Opko Health Released By InvestorsObserver
PR Newswire - Mon Jul 20, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for LINE, GILD, BP, AA and OPK.
AA: 9.96 (-0.03), OPK: 17.21 (+0.45), GILD: 117.66 (+0.22), BP: 37.30 (-0.61), LINE: 5.89 (+0.20)
Research and Markets: Key Pharma News Issue - Gilead will make further oncology deals in 2015
Business Wire - Mon Jul 20, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fz2fmj/key_pharma_news) has announced the addition of the "Key Pharma News Issue" newsletter to their offering.
GILD: 117.66 (+0.22)
Key Pharma News Issue - Gilead will make further oncology deals in 2015
M2 - Mon Jul 20, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqtx6g/key_pharma_news) has announced the addition of the "Key Pharma News Issue" newsletter to their offering. This acquisition bolsters Gilead Sciences' burgeoning oncology pipeline and serves as a statement of intent. Gilead will make further oncology deals in 2015, with a large-scale potentially transformative acquisition by the end of 2016. Key Pharma News covers all major developments in the pharmaceutical industry, spanning key therapy areas including: Cancer, CNS, Autoimmune, Anti-Infectives, Generics and more. The fortnightly newsletter will provide you with the latest news and developments involving pharmaceutical companies worldwide. Being comprehensive and easy to read, Key Pharma News is the time-efficient way to keep up with every pharma development you need to know. Regular sections include: - Corporate Activity - The latest noteworthy acquisition, merger, divestiture and restructuring and capital expenditure news - Agreements - New deals, alliances and collaborations - Product News - The latest product filings, approvals, launches, withdrawals and litigations, worldwide - R&D - News of pipeline updates, late-stage clinical trials, and patent-related developments Your Benefits: - Track the companies that are shaping the industry - identify potential partnering opportunities, keep track of your competitors and highlight acquisition targets. - Understand the latest developments in current and upcoming treatments and research - be at the forefront of research and development - Monitor the highlights from major conferences and meetings across the world - never miss another update - Keep ahead of every important development Key Topics Covered: 1. EpiTherapeutics Acquisition Will Be Start Of Oncology Deals For Gilead In 2015 2. OncoGenex Regains Rights To Custirsen From Teva 3. Curadev/Roche Enter Cancer Immunotherapy Deal 4. ViiV To Help GSK Weather A Tumultuous 2015 5. GSK Oncology Additions To Increase Novartis' Growth Trajectory 6. Biogen Will Continue To Gain Share Of MS Market 7. Esbriet Sales Will Reach Blockbuster Status In 2016 8. Teva Completes Acquisition Of Auspex Pharmaceuticals 9. Outcome Of Perrigo-Mylan-Teva Tussle Will Shape The Generic Industry 10. Xarelto Gains Approval For Additional Indications In China 11. Tecfidera Will Be Leading MS Drug In 2015 12. FDA Approves Ionsys For Acute Postoperative Pain 13. FDA Accepts Zinbryta BLA For MS 14. Pomalyst Meets Accelerated Approval Requirements For r/r MM 15. Lilly's Cyramza Gains Fourth FDA Approval 16. FDA Grants Opdivo Priority Review For Previously Untreated Advanced Melanoma 17. FDA Will Continue To Face Criticism Until Interchangeability And Naming Issues Are Resolved 18. Oncolytic Immunotherapy Will Enter The Market In 2015 19. GSK's Shingles Vaccine To Erode Sales Of Merck's Zostavax 20. Gilead/AbbVie To Eradicate Niche Commercial Opportunities In HCV 21. BMS To Retain Dominant Position In First-Line Advanced Melanoma Setting 22. Follow-Up Announcement Made On Preliminary Findings From Lurasidone Phase III Study 22. Arzerra Phase III Study Meets Primary Endpoint Of PFS In Relapsed CLL For more information visit http://www.researchandmarkets.com/research/tq...harma_news About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PRGO: 189.71 (+0.66), GILD: 117.66 (+0.22), MRK: 58.07 (-0.06), ASPX: 100.96 (unch), NVS: 103.05 (+1.75)
Gilead's Fantastic Growth Expected To Slow
at Investor's Business Daily - Fri Jul 17, 5:48PM CDT
With nearly 400 companies in IBD's biotech industry group, it takes a lot to stand out, and Gilead Sciences (GILD) is doing that with its profit growth. The company's three-year average earnings growth rate of 74% is sixth highest, and its 2014 EPS...
GILD: 117.66 (+0.22), ABBV: 70.52 (-0.04)
Bristol-Myers' HIV-1 Drug Evotaz Gets European Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 17, 3:30PM CDT
Bristol-Myers Squibb Company (BMY) announced that the European Commission has approved Evotaz.
EBIO: 2.91 (+0.01), GILD: 117.66 (+0.22), ANAC: 147.90 (-2.05), BMY: 68.24 (-1.13)
Which Top Biotechs Still In Play After Celgene Rally?
at Investor's Business Daily - Thu Jul 16, 5:45PM CDT
This week's list of leading stocks near buy points includes a healthy dose of medical names, from biotechs to managed care providers. The biotech revival began prior to Celgene's (CELG) 7% jump Wednesday on its $7.2 billion buy of Receptos (RCPT)....
MNK: 124.99 (-1.52), AGN: 314.95 (-0.40), VRX: 253.84 (+14.92), GILD: 117.66 (+0.22), UTHR: 175.10 (+0.50), RCPT: 228.27 (-0.13), MOH: 71.34 (-1.08), REGN: 556.61 (+0.08), CELG: 139.01 (+0.75)
Bristol-Myers Squibb Gets a Mixed Message From Investors
Brian Orelli, The Motley Fool - Motley Fool - 1 hr 18 mins ago
Source: Bristol-Myers Squibb When a company beats revenue expectations by a wide margin, $4.2 billion actual versus a $3.7 billion consensus, as Bristol-Myers Squibb did, you'd expect shares to skyrocket. Instead the pharma is sitting down 1%...
GILD: 117.66 (+0.22), BMY: 68.24 (-1.13)
Gilead Sciences Leads 3 Top-Rated Big Cap Stocks
at Investor's Business Daily - Wed Jul 22, 9:12PM CDT
Combining superior fundamentals with strong chart action can pinpoint top stock watch candidates such as Gilead Sciences. Today's Screen Of The Day, Top Fundamentals, features highly rated firms with three-year sales and earnings growth rates of at...
NFLX: 110.10 (-1.40), AMZN: 482.18 (-6.09), LEN: 52.46 (-0.73), GILD: 117.66 (+0.22), GOOGL: 674.73 (-20.37), MSFT: 46.11 (+0.57), BABA: 83.88 (-0.27)
Gilead (GILD) Presents Encouraging Data on HIV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 22, 1:55PM CDT
Gilead Sciences, Inc. (GILD) presented encouraging detailed 48-week data from the phase III study on tenofovir alafenamide-based regimen for the treatment of HIV.
JNJ: 100.20 (+0.02), GILD: 117.66 (+0.22), SNSS: 3.47 (-0.05), AMAG: 71.31 (-1.23)
US Blood Cancer Drug Market & Pipeline Analysis 2015
M2 - Wed Jul 22, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hp4cd3/us_blood_cancer) has announced the addition of the "US Blood Cancer Drug Market & Pipeline Analysis 2015" report to their offering. Chemotherapeutic drugs are widely used therapeutics for the treatment of blood cancer in US. The future would witness a novel chemotherapeutics which are currently under various stages of research and development. Liposomal, pegylated and other improved versions are being made to offer higher therapeutic benefit along with minimized side effects. This will also help in increasing the number of indications and market volume by introduction of new chemotherapeutic products. They would have higher safety and efficacy levels as compared to their traditional counterparts. It will help in occupying large market shares and compete effectively with presently available drugs. Monoclonal antibodies are known for their superior pharmacological profiles and fewer side effects due to which they are widely accepted. Few monoclonal antibodies have been already introduced in US market. They have been able to generate significant revenues which are encouraging pharmaceutical companies to venture in this segment. Tyrosine kinase inhibitors are another major component of this market which has received lots of commercial success owing to their superior pharmacological efficacy. Both of them are far superior then chemotherapeutics and it is expected that blood cancer drugs belonging to different drug categories would be introduced in US market. Innovative blood cancer therapeutics is likely to generate huge revenues for the pharmaceutical companies in the next few years. However, few hurdles have to be passed like heterogeneous nature of blood cancer; it consists of different cells with different functions and it becomes difficult to eliminate them with single type of therapeutic. In this regard, only single therapeutic for different blood cancers have been introduced in US market till date. This strategy is likely to be followed by other pharmaceutical companies due to which competition in multiple blood cancer segments will increase. Market introduction of such therapeutics is likely to be widely accepted leading to generation of significant revenues. More blood cancer therapeutics is likely to enter in US market due to which its size will increase. "US Blood Cancer Drug Market & Pipeline Analysis 2015" Report Highlights: - Blood Cancer Incidence & Prevalence - Blood Cancer Drug Market Overview - Blood Cancer Drug Market Dynamics - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline Insight - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline: 435 Drugs - Majority Drugs in Phase-I Clinical Trials: 128 Drugs - Marketed Leukemia, Lymphoma & Myeloma Drug Clinical & Patent Analysis - Marketed Leukemia, Lymphoma & Myeloma Drug: 48 Drugs Key Topics Covered: 1. US Blood Cancer Incidence & Prevalence 2. US Blood Cancer Drug Market Overview 3. US Blood Cancer Drug Market Dynamics 4. US Blood Cancer Drug Market Future Prospects 5. Mechanism of Blood Cancer Therapeutics 6. Leukemia Drug Clinical Pipeline by Company & Phase 7. Marketed Leukemia Drug Clinical Insight 8. Lymphoma Drug Clinical Pipeline by Company & Phase 9. Marketed Lymphoma Drug Clinical Insight 10. Multiple Myeloma Drug Clinical Pipeline by Company & Phase 11. Marketed Multiple Myeloma Drug Clinical Insight 12. Multiple Blood Cancer Drug Clinical Pipeline by Company & Phase 13. Marketed Multiple Blood Cancer Drug Clinical Insight 14. Competitive Landscape - ARIAD Pharmaceuticals - Actelion Pharmaceuticals - Amgen - Astellas Pharma - Baxter BioScience - Bayer HealthCare Pharmaceuticals Inc. - Biogen Idec - Bristol-Myers Squibb - CASI Pharmaceuticals - Celera Genomics Group - Celgene Corporation - Eisai Co Ltd - Genmab - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Millennium Pharmaceuticals - Nova Laboratories - Novartis - Onxeo SA - Onyx Pharmaceuticals - Otsuka Pharmaceutical - Pfizer - Roche - SRI International - Scripps Clinic - Seattle Genetics - Southern Research Institute - Tekmira Pharmaceuticals Corporation - Teva Pharmaceutical Industries - Yakult Honsha For more information visit http://www.researchandmarkets.com/research/hp...ood_cancer
BIIB: 385.05 (-6.69), TKMR: 10.73 (+0.39), AMGN: 164.10 (-0.15), GSK: 42.00 (-0.30), BMY: 68.24 (-1.13), CASI: 1.64 (-0.07), JNJ: 100.20 (+0.02), GILD: 117.66 (+0.22), TEVA: 62.51 (unch), ARIA: 8.05 (-0.18), NVS: 103.05 (+1.75), CELGZ: 2.20 (-0.09)
Gilead Sciences' Next Big Move May Not Be What You're Thinking
George Budwell, The Motley Fool - Motley Fool - Wed Jul 22, 9:31AM CDT
Gilead Sciences ' rocket-like growth rate is starting to slow due to pushback from payers over the price of its flagship hepatitis C drugs Harvoni and Sovaldi, along with AbbVie 's competing combo drug, Viekira Pak, beginning to capture a somewhat...
GILD: 117.66 (+0.22)
Hedge Funds Love These 5 Big Stocks -- Should You?
at The Street - Wed Jul 22, 8:23AM CDT
Hedge funds have been piling into these stocks in the last few months. Should you be buying them too?
V: 71.75 (-0.22), LBTYA: 52.08 (-0.46), GILD: 117.66 (+0.22), BABA: 83.88 (-0.27)
Gilead Sciences to Release Second Quarter 2015 Financial Results on Tuesday, July 28, 2015
Business Wire - Tue Jul 21, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2015 financial results will be released on Tuesday, July 28, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead's management will host a conference call to discuss the company's financial results for the second quarter 2015 and provide a general business update.
GILD: 117.66 (+0.22)
Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF)
Business Wire - Tue Jul 21, 1:06PM CDT
Gilead Sciences, Inc. (NASDAQ:GILD) today announced detailed 48-week data from an open-label Phase 3 study (Study 109) evaluating its investigational once-daily single tablet regimen (STR) of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg (E/C/F/TAF) among 1,436 virologically suppressed adult patients switching from tenofovir disoproxil fumarate (TDF)-containing regimens. The study met its primary endpoint by demonstrating non-inferiority of E/C/F/TAF to the TDF-based regimens at Week 48. The study also demonstrated statistical superiority among patients with HIV-1 RNA levels less than 50 copies/mL at Week 48 and statistically significant improvements in bone and renal laboratory parameters. These data were presented in an oral session (session TUAB0102) at the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention (IAS) in Vancouver, Canada.
GILD: 117.66 (+0.22)
Why This Analyst Expects New Alzhemier’s Trials Could Produce the Most Important Drugs in History
ESTMZ - Tue Jul 21, 11:24AM CDT
Welcome to the July 21st edition of This Week on Estimize. We are pleased to be joined by Joe McCann, former biotech analyst and founder of Slingshot Insights, a company that works to provide professional caliber investment tools to sophisticated...
BIIB: 385.05 (-6.69), SPY: 210.18 (-1.19), GILD: 117.66 (+0.22), ZGNX: 20.27 (-0.71), UTHR: 175.10 (+0.50), RTRX: 34.18 (-0.75), LLY: 86.76 (+0.38), CELG: 139.01 (+0.75), XOMA: 1.04 (+0.04)
Gilead Sciences (GILD) Approaches New Downside Target of $117.22
Comtex SmarTrend(R) - Tue Jul 21, 11:06AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $118.33 today and has reached the first level of support at $117.71. Should the shares continue to fall, the support pivots of $117.22 and $116.11 will be of interest.
GILD: 117.66 (+0.22)
Sickle Cell Disease Pipeline Review, H1 2015 - 27 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rrc4sf/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Erytech Pharma SA - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sangamo BioSciences, Inc. - Sanofi - SynZyme Technologies, LLC For more information visit http://www.researchandmarkets.com/research/rr...ickle_cell
JNJ: 100.20 (+0.02), ISIS: 55.08 (-0.30), GILD: 117.66 (+0.22), PFE: 34.78 (-0.10), SGMO: 8.83 (-0.77), BMY: 68.24 (-1.13), NVS: 103.05 (+1.75), XLRN: 31.50 (-0.68)
The Best Deals in Value Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 21, 8:04AM CDT
Source: Federal Reserve Bank of New York via Facebook Investors may have suffered through the worst case of stock market "indigestion" in multiple generations between 2007 and 2009, but the subsequent bull market has produced some of the most...
F: 14.61 (+0.19), IBM: 161.73 (+1.38), GILD: 117.66 (+0.22), BAC: 18.18 (-0.27), AAPL: 125.16 (-0.06)
Nonalcoholic steatohepatitis (NASH) - 2015 Pipeline Analysis
M2 - Tue Jul 21, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kf56cl/nonalcoholic) has announced the addition of the "Nonalcoholic steatohepatitis (NASH) - Pipeline Analysis" report to their offering. This report gives comprehensive insight on the various drugs being developed for the treatment of NASH. The report covers all the drugs being developed in various phases (Discovery, Preclinical & Clinical development). The pipeline focuses on novel medicines covering small molecules, monoclonal antibodies, Recombinant proteins and RNA-based therapeutics, but excludes Off-label, symptom relief drugs, generic combinations. The report also covers hot targets in research for NASH treatments and disease progression biomarkers. This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Nonalcoholic steatohepatitis (NASH) Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future NASH treatment space. NASH is associated with fatty liver, hepatic inflammation, hepatocyte injury and fibrogenesis and may worsen into fibrosis or cirrhosis, liver failure and rarely into liver cancer. Currently, there are no approved drugs for NASH by U.S. Food and Drug Administration (FDA) and there a high unmet clinical need. NASH, if untreated can progress to liver-destroying cirrhosis and potentially cancer. Majority of the NASH pipeline drugs are from specialised small to mid pharmaceutical & biotech companies. As some of the candidates are nearing key R&D milestones, there is a huge competition among large pharmaceutical and biotech companies to acquire these assets. Gilead's acquisition of Phenex FXR program & Boehringer's acquisition of NASH clinical asset from Pharmaxis supports this trend. Diagnosis of NASH still requires histological confirmation and there is a great demand for specific non-invasive diagnosis for distinguishing NASH from other liver diseases. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH. There is a tremendous opportunity for upcoming therapies specific to NASH such as MAbs, RNA-based therapies & Recombinant proteins. These modalities may provide Anti-fibrosis, Anti-inflammatory and metabolic benefits. Key Topics Covered: 1. Report Description 2. Introduction 3. Hot Targets, Mechanisms & Therapies 4. Market Data 5. Pipeline Analysis 6. Small Molecules 7. Large Molecule 8. RNA-based Therapy 9. Recombinant Proteins 10. Antibodies 11. Large Molecules (Unspecified) 12. Other Molecules 13. NASH Drug Analysis based on Mechanisms 14. Major Players - Boehringer Ingelheim - Cerenis Therapeutics - Connexios Life Sciences - Genfit - Gilead Sciences - Intercept - Islet Sciences - Nimbus Therapeutics - Verva Pharmaceuticals - Viking Therapeutics For more information visit http://www.researchandmarkets.com/research/kf...nalcoholic
GILD: 117.66 (+0.22), VKTX: 6.02 (-0.44)
Are Any New FANGs Baring Their Teeth?
at The Street - Mon Jul 20, 10:27AM CDT
The fearsome foursome have been reborn.
AGN: 314.95 (-0.40), AMBA: 122.99 (+0.49), NFLX: 110.10 (-1.40), BIIB: 385.05 (-6.69), GPRO: 63.95 (+2.27), AMZN: 482.18 (-6.09), VRX: 253.84 (+14.92), GILD: 117.66 (+0.22), FB: 95.44 (-1.60), GOOGL: 674.73 (-20.37), REGN: 556.61 (+0.08), CELG: 139.01 (+0.75), MS: 39.94 (-0.60)
Critical Alerts For Linn Energy, Gilead Sciences, BP, Alcoa and Opko Health Released By InvestorsObserver
PR Newswire - Mon Jul 20, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for LINE, GILD, BP, AA and OPK.
AA: 9.96 (-0.03), OPK: 17.21 (+0.45), GILD: 117.66 (+0.22), BP: 37.30 (-0.61), LINE: 5.89 (+0.20)
Research and Markets: Key Pharma News Issue - Gilead will make further oncology deals in 2015
Business Wire - Mon Jul 20, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fz2fmj/key_pharma_news) has announced the addition of the "Key Pharma News Issue" newsletter to their offering.
GILD: 117.66 (+0.22)
Key Pharma News Issue - Gilead will make further oncology deals in 2015
M2 - Mon Jul 20, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqtx6g/key_pharma_news) has announced the addition of the "Key Pharma News Issue" newsletter to their offering. This acquisition bolsters Gilead Sciences' burgeoning oncology pipeline and serves as a statement of intent. Gilead will make further oncology deals in 2015, with a large-scale potentially transformative acquisition by the end of 2016. Key Pharma News covers all major developments in the pharmaceutical industry, spanning key therapy areas including: Cancer, CNS, Autoimmune, Anti-Infectives, Generics and more. The fortnightly newsletter will provide you with the latest news and developments involving pharmaceutical companies worldwide. Being comprehensive and easy to read, Key Pharma News is the time-efficient way to keep up with every pharma development you need to know. Regular sections include: - Corporate Activity - The latest noteworthy acquisition, merger, divestiture and restructuring and capital expenditure news - Agreements - New deals, alliances and collaborations - Product News - The latest product filings, approvals, launches, withdrawals and litigations, worldwide - R&D - News of pipeline updates, late-stage clinical trials, and patent-related developments Your Benefits: - Track the companies that are shaping the industry - identify potential partnering opportunities, keep track of your competitors and highlight acquisition targets. - Understand the latest developments in current and upcoming treatments and research - be at the forefront of research and development - Monitor the highlights from major conferences and meetings across the world - never miss another update - Keep ahead of every important development Key Topics Covered: 1. EpiTherapeutics Acquisition Will Be Start Of Oncology Deals For Gilead In 2015 2. OncoGenex Regains Rights To Custirsen From Teva 3. Curadev/Roche Enter Cancer Immunotherapy Deal 4. ViiV To Help GSK Weather A Tumultuous 2015 5. GSK Oncology Additions To Increase Novartis' Growth Trajectory 6. Biogen Will Continue To Gain Share Of MS Market 7. Esbriet Sales Will Reach Blockbuster Status In 2016 8. Teva Completes Acquisition Of Auspex Pharmaceuticals 9. Outcome Of Perrigo-Mylan-Teva Tussle Will Shape The Generic Industry 10. Xarelto Gains Approval For Additional Indications In China 11. Tecfidera Will Be Leading MS Drug In 2015 12. FDA Approves Ionsys For Acute Postoperative Pain 13. FDA Accepts Zinbryta BLA For MS 14. Pomalyst Meets Accelerated Approval Requirements For r/r MM 15. Lilly's Cyramza Gains Fourth FDA Approval 16. FDA Grants Opdivo Priority Review For Previously Untreated Advanced Melanoma 17. FDA Will Continue To Face Criticism Until Interchangeability And Naming Issues Are Resolved 18. Oncolytic Immunotherapy Will Enter The Market In 2015 19. GSK's Shingles Vaccine To Erode Sales Of Merck's Zostavax 20. Gilead/AbbVie To Eradicate Niche Commercial Opportunities In HCV 21. BMS To Retain Dominant Position In First-Line Advanced Melanoma Setting 22. Follow-Up Announcement Made On Preliminary Findings From Lurasidone Phase III Study 22. Arzerra Phase III Study Meets Primary Endpoint Of PFS In Relapsed CLL For more information visit http://www.researchandmarkets.com/research/tq...harma_news About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PRGO: 189.71 (+0.66), GILD: 117.66 (+0.22), MRK: 58.07 (-0.06), ASPX: 100.96 (unch), NVS: 103.05 (+1.75)
Gilead's Fantastic Growth Expected To Slow
at Investor's Business Daily - Fri Jul 17, 5:48PM CDT
With nearly 400 companies in IBD's biotech industry group, it takes a lot to stand out, and Gilead Sciences (GILD) is doing that with its profit growth. The company's three-year average earnings growth rate of 74% is sixth highest, and its 2014 EPS...
GILD: 117.66 (+0.22), ABBV: 70.52 (-0.04)
Bristol-Myers' HIV-1 Drug Evotaz Gets European Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 17, 3:30PM CDT
Bristol-Myers Squibb Company (BMY) announced that the European Commission has approved Evotaz.
EBIO: 2.91 (+0.01), GILD: 117.66 (+0.22), ANAC: 147.90 (-2.05), BMY: 68.24 (-1.13)
Which Top Biotechs Still In Play After Celgene Rally?
at Investor's Business Daily - Thu Jul 16, 5:45PM CDT
This week's list of leading stocks near buy points includes a healthy dose of medical names, from biotechs to managed care providers. The biotech revival began prior to Celgene's (CELG) 7% jump Wednesday on its $7.2 billion buy of Receptos (RCPT)....
MNK: 124.99 (-1.52), AGN: 314.95 (-0.40), VRX: 253.84 (+14.92), GILD: 117.66 (+0.22), UTHR: 175.10 (+0.50), RCPT: 228.27 (-0.13), MOH: 71.34 (-1.08), REGN: 556.61 (+0.08), CELG: 139.01 (+0.75)
